[ad_1]
The second-quarter sales decline was mostly due to lower demand for the company’s COVID-19 vaccine.
[ad_2]
Source link
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March...